Published: Dec. 13, 2024
Language: Английский
Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 7, 2025
Language: Английский
Citations
1
Inflammopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: May 1, 2025
Language: Английский
Citations
0
Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(11), P. 1104 - 1104
Published: Nov. 13, 2024
Neurodegenerative diseases, such as Alzheimer's disease (AD), are a growing public health crisis, exacerbated by an aging global population and the lack of effective early disease-modifying therapies. Early detection neurodegenerative disorders is critical to delaying symptom onset mitigating progression, but current diagnostic tools often rely on detecting pathology once clinical symptoms have emerged significant neuronal damage has already occurred. While disease-specific biomarkers, amyloid-beta tau in AD, offer precise insights, they too limited scope for broader neurodegeneration screening these conditions. Conversely, general biomarkers like neurofilament light chain (NfL) provide valuable staging information targeted insights. Circulating cell-free DNA (cfDNA), released during cell death, emerging promising biomarker detection. Derived from dying cells, cfDNA can capture both signals offering multi-layered genomic epigenomic information. Though its potential remains under investigation, advances sensitivity, standardized protocols, reference ranges could establish tool screening. methylation signatures, particular, show great promise identifying tissue-of-origin changes, minimally invasive that transform precision neurology. However, further research required address technological challenges validate cfDNA's utility settings. Here, we review recent work assessing AD. With continued advances, play pivotal role shifting care reactive proactive, improving timelines patient outcomes.
Language: Английский
Citations
0
Published: Dec. 13, 2024
Language: Английский
Citations
0